<DOC>
	<DOC>NCT00116662</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.</brief_summary>
	<brief_title>An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<criteria>Diagnosis of common wart(s) Ages between 3 to 11 Other types of wart(s), ie. plantar Currently participating in another clinical study Chronic viral hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Wart(s)</keyword>
	<keyword>Common Wart(s)</keyword>
	<keyword>Children</keyword>
	<keyword>Pediatric</keyword>
	<keyword>3M Pharmaceuticals</keyword>
	<keyword>Resiquimod</keyword>
</DOC>